Related Experiment Video
Updated: Jun 25, 2025

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis
Published on: March 19, 2019
Mitigating candidiasis with acarbose by targeting Candida albicans α-glucosidase: in-silico, in-vitro and
Helma David1, Sahana Vasudevan2,3, Adline Princy Solomon4
1Quorum Sensing Laboratory, Centre for Research in Infectious Diseases (CRID), School of Chemical and Biotechnology, SASTRA Deemed to be University, Thanjavur, 613401, India.
Abstract:
Biofilm-associated candidiasis poses a significant challenge in clinical settings due to the limited effectiveness of existing antifungal treatments. The challenges include increased pathogen virulence, multi-drug resistance, and inadequate penetration of antimicrobials into biofilm structures. One potential solution to this problem involves the development of novel drugs that can modulate fungal virulence and biofilm formation, which is essential for pathogenesis. Resistance in Candida albicans is initiated by morphological changes from yeast to hyphal form. This transition triggers a series of events such as cell wall elongation, increased adhesion, invasion of host tissues, pathogenicity, biofilm formation, and the initiation of an immune response. The cell wall is a critical interface for interactions with host cells, primarily through various cell wall proteins, particularly mannoproteins. Thus, cell wall proteins and enzymes are considered potential antifungal targets. In this regard, we explored α-glucosidase as our potential target which plays a crucial role in processing mannoproteins. Previous studies have shown that inhibition of α-glucosidase leads to defects in cell wall integrity, reduced adhesion, diminished secretion of hydrolytic enzymes, alterations in immune recognition, and reduced pathogenicity. Since α-glucosidase, primarily converts carbohydrates, our study focuses on FDA-approved carbohydrate mimic drugs (Glycomimetics) with well-documented applications in various biological contexts. Through virtual screening of 114 FDA-approved carbohydrate-based drugs, a pseudo-sugar Acarbose, emerged as a top hit. Acarbose is known for its pharmacological potential in managing type 2 diabetes mellitus by targeting α-glucosidase. Our preliminary investigations indicate that Acarbose effectively inhibits C. albicans biofilm formation, reduces virulence, impairs morphological switching, and hinders the adhesion and invasion of host cells, all at very low concentrations in the nanomolar range. Furthermore, transcriptomic analysis reveals the mechanism of action of Acarbose, highlighting its role in targeting α-glucosidase.
Insights
Acarbose effectively inhibits Candida albicans biofilms and reduces virulence by targeting alpha-glucosidase. This FDA-approved drug shows promise for treating challenging fungal infections at nanomolar concentrations.
Area of Science:
- Medical Mycology
- Drug Discovery
- Antifungal Resistance
Background:
- Biofilm-associated candidiasis is a major clinical challenge due to limited treatment efficacy.
- Candida albicans virulence and biofilm formation are critical for pathogenesis.
- Alpha-glucosidase is a key enzyme in mannoprotein processing and a potential antifungal target.
Purpose of the Study:
- To identify novel therapeutic agents targeting alpha-glucosidase for Candida albicans.
- To evaluate the efficacy of FDA-approved glycomimetics against fungal biofilms and virulence.
Main Methods:
- Virtual screening of 114 FDA-approved carbohydrate-based drugs.
- In vitro testing of Acarbose for biofilm inhibition, virulence reduction, and host cell interaction.
- Transcriptomic analysis to elucidate the mechanism of action.
Main Results:
- Acarbose, an alpha-glucosidase inhibitor, was identified as a top hit.
- Acarbose significantly inhibited Candida albicans biofilm formation and reduced virulence at nanomolar concentrations.
- Acarbose impaired morphological switching, adhesion, and invasion of host cells.
Conclusions:
- Acarbose demonstrates potent anti-Candida activity by targeting alpha-glucosidase.
- Acarbose represents a promising therapeutic candidate for biofilm-associated candidiasis.
- Targeting alpha-glucosidase offers a novel strategy to combat drug-resistant fungal infections.

